Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Cancer type

Colorectal

Colorectal cancer.

Must-know

  1. 1

    DYNAMIC: ctDNA-guided adjuvant therapy in stage II colon cancer

    Tie et al. New England Journal of Medicine. 2022.

    455 patients with stage II colon cancer were randomized. Adjuvant chemotherapy was given to 15% with ctDNA-guided care and 28% with standard care. Two-year recurrence-free survival was 93.5% and 92.4%, meeting the noninferiority margin.

    PMID 35657320DOI

  2. 2

    GALAXY: postoperative ctDNA and adjuvant chemotherapy in colorectal cancer

    Kotani et al. Nature Medicine. 2023.

    In this prospective CIRCULATE-Japan analysis of resectable colorectal cancer, postoperative ctDNA positivity identified patients with stage II or III disease who had a reported benefit from adjuvant chemotherapy (hazard ratio 6.59).

    PMID 36646802DOI

  3. 3

    Postoperative ctDNA in stage I–III colorectal cancer

    Reinert et al. JAMA Oncology. 2019.

    In stages I–III colorectal cancer, ctDNA detection after treatment preceded radiographic relapse by a mean of 8.7 months (range 0.8–16.5).

    PMID 31070691DOI

Listed when a study is a randomized or prospective interventional ctDNA or MRD trial, is cited in NCCN or ESMO guidance, or is a prospective validation cohort in a high-impact journal. Shorter lists mean fewer studies met that rule. No test is ranked.

Publications and presentations

Presentations

Accruing studies for Colorectal

Trials

ALTAIR: trifluridine/tipiracil did not significantly extend DFS after ctDNA turned positive in resected colorectal cancer

In the phase 3 ALTAIR trial published in Nature Medicine on June 8, 2026, 243 patients with resected colorectal cancer who became tumor-informed ctDNA-positive without radiographic disease were randomized to trifluridine/tipiracil or placebo; median disease-free survival was 9.30 versus 5.55 months (HR 0.79; P = 0.107), so the primary endpoint was not met.

Nature Medicine

DYNAMIC-III: ctDNA split recurrence risk in stage III colon cancer, and de-escalation missed non-inferiority

In the phase 2/3 DYNAMIC-III trial published in Nature Medicine on October 20, 2025, 702 of 968 evaluable patients with stage III colon cancer were ctDNA-negative 5 to 6 weeks after surgery; 3-year recurrence-free survival was 87% if ctDNA-negative and 49% if ctDNA-positive, de-escalation in the ctDNA-negative group did not meet non-inferiority (85.3% versus 88.1%), and escalation in the ctDNA-positive group did not improve 2-year recurrence-free survival (51% versus 61%).

Nature Medicine

GIColorectalTier 2PinnedMRD / ctDNABiomarkers

Risk stratification by circulating tumor DNA-based pretreatment genomic profile and post-operative molecular residual disease detection in resectable colorectal oligometastases: PRECISION, a prospective multicenter study

In the prospective PRECISION study of 118 eligible patients with resectable colorectal oligometastases, pretreatment Guardant360 genomic profiling and postoperative Guardant Reveal MRD were each independently associated with shorter recurrence-free survival (multivariable HRs 3.28 and 4.07); patients with both a poor genomic profile and postoperative MRD had the highest recurrence risk (RFS HR 13.28), and those with an optimal profile and undetected MRD had a 2-year RFS of 77.8%.

ESMO Open

BESPOKE CRC: postoperative ctDNA positivity tracked with shorter disease-free survival in stage II and III disease

In the final MRD analysis of the observational BESPOKE CRC study presented at ASCO GI 2025, ctDNA positivity in the postoperative window was associated with inferior disease-free survival in stage II disease (HR 10.4) and stage III disease (HR 10.1) among patients with a result in that window.

Journal of Clinical Oncology

GIColorectalTier 3PinnedMRD / ctDNATrials

Natera Announces Clinical Collaboration with Incyte on Interventional Phase II Study in Colorectal Cancer

NCT07823322 (NEXERA-204) is an Incyte-sponsored, not-yet-recruiting, single-arm phase 2 study of INCA33890 in about 40 adults with Signatera-positive, microsatellite-stable stage II/III colorectal cancer after curative resection and chemotherapy, with ctDNA clearance at 3 months as the primary endpoint; Natera announced a clinical collaboration on this study on November 10, 2026.

Natera, Inc.

GIColorectalTier 3PinnedMRD / ctDNABiomarkers

Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Cytoreductive Surgery for Colorectal Peritoneal Metastases

In a single-center series of 87 patients undergoing cytoreductive surgery for colorectal peritoneal metastases, postoperative ctDNA was detectable in 30 of 83 (36%) and was associated with shorter recurrence-free survival (HR 3.5), peritoneal recurrence-free survival (HR 3.1), and overall survival (HR 6.7); the abstract does not name the assay, and the paper is about peritoneal, not liver, metastases.

Annals of Surgical Oncology

OtherTier 3PinnedMRD / ctDNAConference data

Signatera Monitoring During First-Line Immunotherapy Showed ctDNA Clearance is Associated with Long-Term Survival Across Four Metastatic Cancers

A Natera press release dated November 5, 2026, describes a real-world SITC analysis of 424 patients on first-line immunotherapy for stage IV melanoma, kidney cancer, MSI-H colorectal cancer, or NSCLC: people with two consecutive negative Signatera results had 36-month overall survival of 93.2% versus 77.9% in all others (HR 0.24, P=0.0003), and among those complete molecular responders overall survival was 93.5% if immunotherapy continued and 89.4% if it stopped (P=0.42). These figures are from the company press release; the official SITC/JITC abstract was not retrieved.

Natera, Inc. company press release

Alpha-CORRECT: surveillance ctDNA positivity was strongly associated with recurrence in stage III colorectal cancer

In the observational alpha-CORRECT cohort of 124 patients with stage III colorectal cancer presented at ASCO GI 2025, a tumor-informed assay using up to 200 variants found that ctDNA positivity during surveillance was associated with recurrence (HR 49.6; 95% CI 16.6 to 148.3), with a median lead time of 10.4 months before a clinical diagnosis of recurrence.

Journal of Clinical Oncology